UPDATE: Xenetic Reports Partner, PJSC Pharmsynthez, Issued Data From Phase 3 Trial Of PolyXen To Develop Treatment For Anemia In Patients With Chronic Kidney Disease; PolyXen Platform Used To Develop Epolong, Which Helps Kidneys Promote Cell Production